AstraZeneca (LSE:AZN) Wins Two EU Cancer Approvals And Starts Abbisko Lung Trial

AstraZeneca (LSE:AZN) secured European Union approval for Enhertu as the first HER2-directed antibody drug conjugate with a tumor agnostic indication.

The European Medicines Agency recommended Datroway for first line treatment of metastatic triple negative breast cancer.

AstraZeneca and Abbisko Therapeutics initiated a multicenter Phase I/II trial combining Tagrisso with an oral PD L1 inhibitor in EGFR mutated, PD L1 positive NSCLC.

AstraZeneca sits at the center of a fast moving shift in...

How This Fits Into The AstraZeneca Narrative The Enhertu and Datroway news lines up with the narrative focus on a broad late stage oncology pipeline that targets chronic and age related diseases, by adding further tumor specific and tumor agnostic us... [3314 chars]